Abong, Raphael Awah
Amambo, Glory N.
Chounna Ndongmo, Patrick W.
Njouendou, Abdel Jelil
Ritter, Manuel
Beng, Amuam Andrew
Esum, Mathias Eyong
Deribe, Kebede
Fru-Cho, Jerome
Fombad, Fanny F.
Nji, Theobald Mue
Enyong, Peter Ivo
Poole, Catherine B.
Pfarr, Kenneth
Hoerauf, Achim
Carlow, Clotilde K. S.
Wanji, Samuel http://orcid.org/0000-0003-0022-8366
Article History
Received: 4 April 2020
Accepted: 23 September 2020
First Online: 2 October 2020
Change Date: 18 January 2021
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: Ethical approval was obtained from the National Ethics Committee for Human Health Research (Ref: N°2015/09/641/CE/CNERSH/SP). An administrative authorization was obtained from the Ministry of Public Health (Ref: N<sup>o</sup>48/L/MINSANTE/SG/DLMEP/PNLO). At the health system level and in the study communities, details on the benefits and potential risk of the study were explained to study volunteers, community leaders (Quarter-heads or Chiefs), CDDs, front line health personnel (FLHPs) and Regional Onchocerciasis Coordinators (ROC) using information sheets. A written consent form was signed or thumb-printed by adult participants and an assent form signed by parents or guardians of children (< 18 years of age) who enrolled in the study. The name, sex, age, village name, community code, contact information (telephone number), history of IVM-intake and an assigned numerical participant ID number was recorded on the recruitment form. No oral informed consent was taken.
: Not applicable.
: The authors declare that they have no competing interests.